Antimicrobial Random Peptide Mixtures Eradicate Biofilms and Inhibit Mouse Models of Infection.

Hannah E Caraway, Jonathan Z Lau, Bar Maron, Myung Whan Oh, Yael Belo, Aya Brill, Einav Malach, Nahed Ismail, Zvi Hayouka, Gee W Lau
Author Information
  1. Hannah E Caraway: Department of Pathobiology, University of Illinois at Urbana-Champaign, Urbana, IL 61802, USA.
  2. Jonathan Z Lau: Department of Pathobiology, University of Illinois at Urbana-Champaign, Urbana, IL 61802, USA.
  3. Bar Maron: Institute of Biochemistry, Food Science and Nutrition, The Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Rehovot 76100, Israel.
  4. Myung Whan Oh: Department of Pathobiology, University of Illinois at Urbana-Champaign, Urbana, IL 61802, USA.
  5. Yael Belo: Institute of Biochemistry, Food Science and Nutrition, The Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Rehovot 76100, Israel.
  6. Aya Brill: Institute of Biochemistry, Food Science and Nutrition, The Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Rehovot 76100, Israel.
  7. Einav Malach: Institute of Biochemistry, Food Science and Nutrition, The Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Rehovot 76100, Israel.
  8. Nahed Ismail: Department of Pathology, College of Medicine, University of Illinois at Chicago, 840 South Wood Street, Chicago, IL 60612, USA.
  9. Zvi Hayouka: Institute of Biochemistry, Food Science and Nutrition, The Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Rehovot 76100, Israel.
  10. Gee W Lau: Department of Pathobiology, University of Illinois at Urbana-Champaign, Urbana, IL 61802, USA.

Abstract

Antibiotic resistance is one of the greatest crises in human medicine. Increased incidents of antibiotic resistance are linked to clinical overuse and overreliance on antibiotics. Among the ESKAPE pathogens, , especially carbapenem-resistant isolates, has emerged as a significant threat in the context of blood, urinary tract, lung, and wound infections. Therefore, new approaches that limit the emergence of antibiotic resistant are urgently needed. Recently, we have shown that random peptide mixtures (RPMs) are an attractive alternative class of drugs to antibiotics with strong safety and pharmacokinetic profiles. RPMs are antimicrobial peptide mixtures produced by incorporating two amino acids at each coupling step, rendering them extremely diverse but still defined in their overall composition, chain length, and stereochemistry. The extreme diversity of RPMs may prevent bacteria from evolving resistance rapidly. Here, we demonstrated that RPMs rapidly and efficiently kill different strains of , inhibit biofilm formation, and disrupt mature biofilms. Importantly, RPMs attenuated bacterial burden in mouse models of acute pneumonia and soft tissue infection and significantly reduced mouse mortality during sepsis. Collectively, our results demonstrate RPMs have the potential to be used as powerful therapeutics against antibiotic-resistant .

Keywords

References

  1. Antimicrob Agents Chemother. 2003 May;47(5):1700-6 [PMID: 12709343]
  2. Am J Transl Res. 2019 Jul 15;11(7):3919-3931 [PMID: 31396309]
  3. ACS Infect Dis. 2021 Mar 12;7(3):672-680 [PMID: 33650856]
  4. Biomolecules. 2018 May 21;8(2): [PMID: 29883434]
  5. Microb Biotechnol. 2018 Nov;11(6):1027-1036 [PMID: 29488347]
  6. Microb Genom. 2019 Oct;5(10): [PMID: 31599224]
  7. Antibiotics (Basel). 2020 Oct 13;9(10): [PMID: 33066005]
  8. mBio. 2015 Mar 24;6(2): [PMID: 25805730]
  9. Anticancer Res. 2016 Aug;36(8):4375 [PMID: 27466586]
  10. Chem Commun (Camb). 2019 Feb 12;55(14):2007-2014 [PMID: 30688322]
  11. ACS Infect Dis. 2021 Feb 12;7(2):493-505 [PMID: 33522241]
  12. FEMS Microbiol Lett. 2006 May;258(1):72-7 [PMID: 16630258]
  13. Expert Opin Drug Discov. 2022 Jan;17(1):1-4 [PMID: 34560823]
  14. Angew Chem Int Ed Engl. 2017 Jul 3;56(28):8099-8103 [PMID: 28557193]
  15. APMIS. 2017 Apr;125(4):365-375 [PMID: 28407421]
  16. Antimicrob Agents Chemother. 2007 Jul;51(7):2324-8 [PMID: 17438042]
  17. Infect Immun. 2000 Nov;68(11):6139-46 [PMID: 11035717]
  18. PLoS One. 2013 Oct 18;8(10):e76521 [PMID: 24204634]
  19. J Intensive Care Med. 2017 Oct;32(9):528-534 [PMID: 26902255]
  20. Mol Inform. 2020 Nov;39(11):e2000059 [PMID: 32578959]
  21. Expert Rev Anti Infect Ther. 2018 Jan;16(1):51-65 [PMID: 29235402]
  22. Annu Rev Microbiol. 2010;64:357-72 [PMID: 20528688]
  23. Antimicrob Agents Chemother. 2007 Apr;51(4):1530-3 [PMID: 17220422]
  24. Mol Microbiol. 2015 Jul;97(1):151-65 [PMID: 25846124]
  25. PLoS One. 2017 Apr 3;12(4):e0174518 [PMID: 28369127]
  26. Proc Biol Sci. 2006 Jan 22;273(1583):251-6 [PMID: 16555795]
  27. BMC Med. 2018 Jun 4;16(1):78 [PMID: 29860943]
  28. J Am Soc Nephrol. 2007 Nov;18(11):2810-6 [PMID: 17942949]
  29. Curr Top Med Chem. 2017;17(5):620-628 [PMID: 27411322]
  30. Molecules. 2021 Sep 05;26(17): [PMID: 34500835]
  31. Clin Microbiol Rev. 2020 May 13;33(3): [PMID: 32404435]
  32. Prog Chem Org Nat Prod. 2019;110:99-141 [PMID: 31621012]
  33. Front Neurosci. 2017 Feb 14;11:73 [PMID: 28261050]
  34. FEMS Microbiol Rev. 2018 Jan 1;42(1): [PMID: 29069382]
  35. Front Microbiol. 2020 Oct 06;11:589234 [PMID: 33123117]
  36. Chem Commun (Camb). 2020 Oct 14;56(80):12053-12056 [PMID: 32902531]
  37. Infect Drug Resist. 2018 Oct 10;11:1645-1658 [PMID: 30349322]
  38. Microb Pathog. 2019 Nov;136:103712 [PMID: 31491551]
  39. Crit Care. 2007;11(3):134 [PMID: 17543135]
  40. J Antimicrob Chemother. 2015 Dec;70(12):3291-7 [PMID: 26318190]
  41. Nat Microbiol. 2020 Jan;5(1):67-75 [PMID: 31740764]
  42. J Bacteriol. 2009 Apr;191(7):2414-8 [PMID: 19136598]
  43. Microbiol Mol Biol Rev. 2003 Dec;67(4):686-723 [PMID: 14665680]
  44. Curr Biol. 2016 Jan 11;26(1):R14-9 [PMID: 26766224]
  45. Adv Exp Med Biol. 2015;830:157-79 [PMID: 25366227]
  46. Nat Biotechnol. 2019 Oct;37(10):1186-1197 [PMID: 31427820]
  47. Front Public Health. 2014 Sep 16;2:145 [PMID: 25279369]
  48. Pathogens. 2021 Mar 19;10(3): [PMID: 33808905]
  49. Nat Rev Drug Discov. 2013 Dec;12(12):963 [PMID: 24232373]
  50. Micromachines (Basel). 2021 Nov 29;12(12): [PMID: 34945330]
  51. Eur J Biochem. 2002 Aug;269(16):3869-80 [PMID: 12180963]
  52. Infect Immun. 2020 Mar 23;88(4): [PMID: 31988172]
  53. J Am Chem Soc. 2020 Jun 17;142(24):10856-10862 [PMID: 32432858]
  54. Microbiol Mol Biol Rev. 2010 Sep;74(3):417-33 [PMID: 20805405]
  55. Infect Immun. 2015 Apr;83(4):1339-46 [PMID: 25605768]
  56. Nat Rev Drug Discov. 2011 Dec 16;11(1):37-51 [PMID: 22173434]
  57. J Am Chem Soc. 2013 Oct 23;135(42):15738-15741 [PMID: 24102563]
  58. Antimicrob Agents Chemother. 2011 Mar;55(3):947-53 [PMID: 21173183]
  59. Nat Rev Microbiol. 2007 Dec;5(12):939-51 [PMID: 18007677]
  60. PLoS One. 2019 May 9;14(5):e0216669 [PMID: 31071184]
  61. Chem Commun (Camb). 2016 Jun 4;52(44):7102-5 [PMID: 27161246]
  62. Int J Antimicrob Agents. 2016 Nov;48(5):492-497 [PMID: 27542315]
  63. Lancet Infect Dis. 2019 Nov;19(11):e392-e398 [PMID: 31427174]
  64. J Pept Sci. 2018 Jul;24(7):e3088 [PMID: 29873139]
  65. Nat Rev Microbiol. 2018 Jul;16(7):397-409 [PMID: 29720707]
  66. J Infect Dis. 2008 Apr 15;197(8):1079-81 [PMID: 18419525]
  67. Nat Rev Microbiol. 2019 Apr;17(4):247-260 [PMID: 30760902]
  68. J Am Chem Soc. 2009 Jun 10;131(22):7609-17 [PMID: 19445503]
  69. Clin Microbiol Rev. 2002 Apr;15(2):167-93 [PMID: 11932229]
  70. Annu Rev Microbiol. 2003;57:677-701 [PMID: 14527295]
  71. J Comput Biol. 2018 Sep;25(9):1059-1070 [PMID: 29927616]
  72. Cell Host Microbe. 2019 Jul 10;26(1):15-21 [PMID: 31295420]
  73. Front Microbiol. 2018 May 07;9:898 [PMID: 29867809]
  74. Pathogens. 2021 Mar 24;10(4): [PMID: 33804894]
  75. J Am Chem Soc. 2013 Aug 14;135(32):11748-51 [PMID: 23909610]
  76. Front Microbiol. 2020 Oct 16;11:582779 [PMID: 33178164]
  77. Curr Top Microbiol Immunol. 2008;322:107-31 [PMID: 18453274]
  78. Proc Natl Acad Sci U S A. 1988 Feb;85(3):910-3 [PMID: 3277183]

Grants

  1. HL142626/United States National Institute of Health
  2. HL090699/United States National Institute of Health
  3. Joint Research and Innovation Seed Grant/Hebrew University of Jerusalem and the University of Illinois

Word Cloud

Created with Highcharts 10.0.0RPMsresistanceantibioticpeptidemixturesantibioticsrandomrapidlybiofilmsmouseacutepneumoniasofttissueinfectionsepsisAntibioticonegreatestcriseshumanmedicineIncreasedincidentslinkedclinicaloveruseoverrelianceAmongESKAPEpathogensespeciallycarbapenem-resistantisolatesemergedsignificantthreatcontextbloodurinarytractlungwoundinfectionsThereforenewapproacheslimitemergenceresistanturgentlyneededRecentlyshownattractivealternativeclassdrugsstrongsafetypharmacokineticprofilesantimicrobialproducedincorporatingtwoaminoacidscouplingsteprenderingextremelydiversestilldefinedoverallcompositionchainlengthstereochemistryextremediversitymaypreventbacteriaevolvingdemonstratedefficientlykilldifferentstrainsinhibitbiofilmformationdisruptmatureImportantlyattenuatedbacterialburdenmodelssignificantlyreducedmortalityCollectivelyresultsdemonstratepotentialusedpowerfultherapeuticsantibiotic-resistantAntimicrobialRandomPeptideMixturesEradicateBiofilmsInhibitMouseModelsInfectionAcinetobacterbaumannii

Similar Articles

Cited By